(Q38554626)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

review article

1 reference

title

Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

hepatocellular carcinoma

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Mario Scartozzi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

Vincenzo Ostilio Palmieri

20 February 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Luca Faloppi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Giuseppe Palasciano

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Gioacchino Angarano

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Oronzo Brunetti

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Attilio Guarini

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

16

Nicola Silvestris

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Antonio Gnoni

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Antonio Russo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Antonella Licchetta

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Luigi Lupo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Vincenzo Memeo

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Salvatore Pisconti

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Vito Lorusso

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

language of work or name

English

0 references

publication date

27 July 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Therapeutic Targets

20 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

1623-1635

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26212068%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Hepatocellular carcinoma: clinical frontiers and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

The role of targeted therapy for gastrointestinal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Targeted therapies in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Targeted therapies for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Monoclonal antibodies in gastrointestinal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Epigenetics in human disease and prospects for epigenetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Recombinant human DNA (cytosine-5) methyltransferase. I. Expression, purification, and comparison of de novo and maintenance methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Identification of novel methylation markers in hepatocellular carcinoma using a methylation array

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Pharmacological unmasking microarray approach-based discovery of novel DNA methylation markers for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Loss of heterozygosity and methylation of multiple tumor suppressor genes on chromosome 3 in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

The role of epigenetic events in genotoxic hepatocarcinogenesis induced by 2-acetylaminofluorene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

p16 Hypermethylation in the early stage of hepatitis B virus-associated hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Chronic viral hepatitis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Methylated cysteine dioxygenase-1 gene promoter in the serum is a potential biomarker for hepatitis B virus-related hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Methylation of serum insulin-like growth factor-binding protein 7 promoter in hepatitis B virus-associated hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Quantification of tumor DNA in serum and vascular invasion of human hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Detection of TFPI2 methylation in the serum of hepatocellular carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Methylation status of genes upregulated by demethylating agent 5-aza-2'-deoxycytidine in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

DNA methyltransferase inhibitor zebularine inhibits human hepatic carcinoma cells proliferation and induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Preferential response of cancer cells to zebularine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Origins and Mechanisms of miRNAs and siRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

MicroRNA expression, survival, and response to interferon in liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Specificity, duplex degradation and subcellular localization of antagomirs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Current status of miRNA-targeting therapeutics and preclinical studies against gastroenterological carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Treatment of HCV infection by targeting microRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Methylation-associated silencing of microRNA-34b in hepatocellular carcinoma cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Cancer epigenetics reaches mainstream oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeuti

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

MiR-376a and histone deacetylation 9 form a regulatory circuitry in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Angiogenesis in chronic liver disease and its complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Cell biology. Beyond clotting: the powers of platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Paraneoplastic thrombocytosis in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Platelets Strongly Induce Hepatocyte Proliferation with IGF-1 and HGF In Vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Platelets harness the immune response to drive liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Platelets mediate cytotoxic T lymphocyte-induced liver damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Cellular and molecular pathways linking inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Macrophage activation and polarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Cancer-promoting tumor-associated macrophages: new vistas and open questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Targeting the PD-1 pathway: a promising future for the treatment of melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Involvement of glypican-3 in the recruitment of M2-polarized tumor-associated macrophages in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Hepatic stellate cells and liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

The role of the myofibroblast in tumor stroma remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Paracrine activation of hepatic stellate cells in platelet-derived growth factor C transgenic mice: evidence for stromal induction of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Hypotheses on the role of transforming growth factor-beta in the onset and progression of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354

Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1071354